� � � � � � � � � NSCLC � � � � � � �
CSCO-ESMO � � � � � JSMO/KSMO/MOS/SSO/TOS � � �
Wu YL, et al. Ann Oncol. 2019 Feb 1;30(2):171-210.
IV � NSCLC � � � � � � � (ALK/BRAF/EGFR/ROS1)
PS 0-1
� � � � � �
� � � � � � /
� � � � � � �
� � (4� � )—> � � � �
� � /
� � � �
� � � � � � /
� � � � � +
� � + � � �
(4-6 � � )—> � � �
� � � /
� � � � �
4-6 � � �
� � /� � � � � � � /� � � � �
� � /� � � � � � /� � � � � � � /
� � � � � � � /� � � � � � � /
� � � � � � /� � � � � � � /� � � � � � � /� � � � � rab-
PC±
� � � � � � � � /� � �
4-6 � � �
� � � �
<70 � � PS 2
≥70 � � PS 0-2
� � � � � � � � � � � � � � � � �
� �
� � � � �
BSC
� � � � � �
/ipilimumab
PS 0-1
� � � �
� TMB
(≥ 10 � � /Mb)
PD-L1 ≥ 50%
PD
� � � � �
� � � � (� � )� � � � �
(� � )� � � � � (� � )� ±
� � � � � (� � � � � )
PD
PS 0-2
PS 3-4
� � PD-L1 � � � �
PS 0-1
<70 � � PS 2 � �
� � ≥ 70 � � PS 0-2
PS 3-4
PR/SD
� � � � � � � � � � � � � � � � � � � �
(PD-L1>1%) � � � � � � � � � � � � � � � � /
� � � � � � � � � /� � � � � � � � �
KN024
KN042
CM227
KN189
IM150
� � �
BSC
� � � �
CM057
CM078
KN010
OAK
